Croda Completes Global EXCiPACT Accreditation
The company is the first multi-site excipient supplier to achieve accreditation across production facilities.
Croda announced that all its global excipient manufacturing sites have completed EXCiPACT audit requirements and have been certified according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard. The certifications are given after manufacturing processes, quality systems, quality management, and storage and distribution facilities are inspected during audits.
"This achievement brings significant value to both Croda and our customers, reducing the audit burden on both sides whilst maintaining confidence in Croda's compliance to the demanding standards of the pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT good manufacturing (GMP) standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards," said Dave Cherry, managing director of Croda’s Health Care business, in a press statement.
Source: Croda
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
